Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bauss

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Bone|September 26, 2006
Effects of ibandronate on bone quality: preclinical studiesF Bauss, D W Dempster
Infection and Immunity|July 1, 1987
Tumor necrosis factor mediates endotoxic effects in miceF Bauss, W Dröge, D N Männel
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|July 5, 2001
The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administrationF Bauss, K Lang, C Dony, et al.
Bone|January 1, 1992
Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related proteinR Rizzoli, J Caverzasio, F Bauss, et al.
Reviews of Infectious Diseases|September 1, 1987
Tumor necrosis factor: a cytokine involved in toxic effects of endotoxinD N Männel, H Northoff, F Bauss, et al.
Calcified Tissue International|September 1, 1996
Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in ratsF Bauss, A Esswein, K Reiff, et al.
Clinical Nephrology|August 12, 2000
Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failureZ Geng, M C Monier-Faugere, F Bauss, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 17, 1998
Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in ratsS Lalla, L A Hothorn, N Haag, et al.
Bone|April 25, 2000
Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysisM Juraschek, M J Seibel, H W Woitge, et al.
The Journal of Bone and Joint Surgery. British Volume|March 4, 2000
Treatment with ibandronate preserves bone in experimental tumour-induced bone lossA H Kurth, S Z Kim, I Sedlmeyer, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Bone|September 26, 2006
Effects of ibandronate on bone quality: preclinical studiesF Bauss, D W Dempster
Infection and Immunity|July 1, 1987
Tumor necrosis factor mediates endotoxic effects in miceF Bauss, W Dröge, D N Männel
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|July 5, 2001
The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administrationF Bauss, K Lang, C Dony, et al.
Bone|January 1, 1992
Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related proteinR Rizzoli, J Caverzasio, F Bauss, et al.
Reviews of Infectious Diseases|September 1, 1987
Tumor necrosis factor: a cytokine involved in toxic effects of endotoxinD N Männel, H Northoff, F Bauss, et al.
Calcified Tissue International|September 1, 1996
Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in ratsF Bauss, A Esswein, K Reiff, et al.
Clinical Nephrology|August 12, 2000
Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failureZ Geng, M C Monier-Faugere, F Bauss, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 17, 1998
Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in ratsS Lalla, L A Hothorn, N Haag, et al.
Bone|April 25, 2000
Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysisM Juraschek, M J Seibel, H W Woitge, et al.
The Journal of Bone and Joint Surgery. British Volume|March 4, 2000
Treatment with ibandronate preserves bone in experimental tumour-induced bone lossA H Kurth, S Z Kim, I Sedlmeyer, et al.
Pageof 3